Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. - Owen, C.N.; Bai, X.; Quah, T.; Lo, S.N.; Allayous, C.; Callaghan, S.; Martínez-Vila, C.; Wallace, R.; Bhave, P.; Reijers, I.L.M.; Thompson, N.; Vanella, V.; et al. (Annals of Oncology, 2021)